BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15860144)

  • 1. 10 questions about using apomorphine for Parkinson disease.
    Dewey RB
    Neurologist; 2005 May; 11(3):190-2. PubMed ID: 15860144
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of apomorphine in clinical practice.
    MacMahon DG
    Adv Neurol; 1999; 80():529-33. PubMed ID: 10410767
    [No Abstract]   [Full Text] [Related]  

  • 3. Future delivery systems for apomorphine in patients with Parkinson's disease.
    van Laar T; Van der Geest R; Danhof M
    Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
    [No Abstract]   [Full Text] [Related]  

  • 4. New treatment for people with Parkinson's.
    FDA Consum; 2004; 38(4):5. PubMed ID: 15346564
    [No Abstract]   [Full Text] [Related]  

  • 5. Apomorphine-subcutaneous--Bertek/Britannia.
    Drugs R D; 2004; 5(4):211-2. PubMed ID: 15230626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
    Wenning GK; Bösch S; Luginger E; Wagner M; Poewe W
    Adv Neurol; 1999; 80():545-8. PubMed ID: 10410769
    [No Abstract]   [Full Text] [Related]  

  • 7. Intranasal apomorphine rescue therapy for parkinsonian "off" periods.
    Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY
    Clin Neuropharmacol; 1996 Jun; 19(3):193-201. PubMed ID: 8726538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent atrial fibrillation after subcutaneous apomorphine.
    Ardolino G; D'Adda E; Nobile-Orazio E
    Parkinsonism Relat Disord; 2008; 14(2):173-4; author reply 175. PubMed ID: 17632031
    [No Abstract]   [Full Text] [Related]  

  • 9. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
    Stacy M; Silver D
    Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Candidate patient for subcutaneous apomorphine injection].
    Chacón JR; Mata M
    Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sleep attacks with apomorphine.
    Homann CN; Suppan K; Wenzel K; Ivanic G; Kriechbaum N; Ott E
    Wien Klin Wochenschr; 2002 Jun; 114(10-11):430-1. PubMed ID: 12708100
    [No Abstract]   [Full Text] [Related]  

  • 12. Practical considerations in the use of apomorphine injectable.
    Bowron A
    Neurology; 2004 Mar; 62(6 Suppl 4):S32-6. PubMed ID: 15037670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pragmatic use of apomorphine at the end of life.
    Dewhurst F; Lee M; Wood B
    Palliat Med; 2009 Dec; 23(8):777-9. PubMed ID: 19837701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Candidate patient for treatment with continuous apomorphine infusion].
    Martí MJ; Kulisevsky J
    Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute lethargy after abrupt apomorphine withdrawal in Parkinson's disease.
    Cavallieri F; Fraix V; Meoni S; Krack P; Moro E; Castrioto A
    J Neurol Sci; 2019 Sep; 404():44-46. PubMed ID: 31325667
    [No Abstract]   [Full Text] [Related]  

  • 17. Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease.
    Pot C; Oppliger R; Castillo V; Coeytaux A; Hauser C; Burkhard PR
    Neurology; 2005 Jan; 64(2):392-3. PubMed ID: 15668455
    [No Abstract]   [Full Text] [Related]  

  • 18. Sublingual apomorphine (Kynmobi) for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Oct; 62(1609):165-166. PubMed ID: 33429410
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection.
    Hauser RA; Isaacson S; Clinch T;
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1171-6. PubMed ID: 25239603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ; Sesar-Ignacio Á
    Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.